A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial

Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.
This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.

开始日期2026-12-01

申办/合作机构

Singapore National Eye Centre Pte Ltd.

NCT07695298

/ Recruiting临床4期IIT

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

开始日期2026-07-01

申办/合作机构

Cincinnati Eye Institute

[+1]

JPRN-jRCTs031260199

/ Recruiting临床4期

Study to Investigate the Prolonged Effects of Faricimab Combined with Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration

开始日期2026-06-08

申办/合作机构-

100 项与法瑞西单抗相关的临床结果

登录后查看更多信息

100 项与法瑞西单抗相关的转化医学

登录后查看更多信息

100 项与法瑞西单抗相关的专利（医药）

登录后查看更多信息

554

项与法瑞西单抗相关的文献（医药）

2026-08-01·Photodiagnosis and Photodynamic Therapy

Rapid vascular pruning and remodeling in refractory type 1 macular neovascularization: A quantitative swept-source OCT angiography study of Faricimab

Article

作者: Liu, Yuanyuan ; Yu, Jinguo ; Liu, Yitong ; Su, Wenqi ; Yang, Likun ; Wang, Ruiying ; Wu, Xiaohan ; Zhou, Wei

PURPOSE:

To evaluate the structural impact of intravitreal faricimab on the neovascular network in treatment-resistant Type 1 macular neovascularization (MNV) using quantitative swept-source optical coherence tomography angiography (SS-OCTA).

METHODS:

A retrospective, single-center cohort study was conducted on 21 eyes with Type 1 MNV (including polypoidal choroidal vasculopathy) that were unresponsive to intensive intravitreal anti-VEGF therapy. Patients underwent switching therapy with a single faricimab injection and were evaluated at baseline and Day 14. Quantitative SS-OCTA analysis included perfusion indices, vascular component segmentation (trunk vs. capillary), and fractal analysis (fractal dimension [FD] and lacunarity) to quantify lesion complexity and pruning.

RESULTS:

Despite a heavy prior treatment burden (mean 11.8 ± 6.5 injections), significant functional and anatomical improvements were observed. BCVA improved (P = 0.0088), and maximum pigment epithelial detachment height decreased (P = 0.0008) with reductions in CFT and SFCT. Crucially, SS-OCTA revealed profound network regression with reduced perfusion area (P = 0.0002) and vessel density (P = 0.0019). Component analysis demonstrated the regression of both recalcitrant trunk and capillary vessels. This vascular remodeling was confirmed by decreased branching complexity (intersection points, P = 0.0017; FD, P = 0.001) and increase in lacunarity (P = 0.0102), quantitatively indicating the "pruning" of the neovascular tree.

CONCLUSIONS:

Intravitreal faricimab demonstrated rapid regression of neovascular architecture in refractory MNV. Quantitative SS-OCTA findings suggest that dual Ang-2/VEGF-A inhibition may contribute to vascular pruning of both trunk and capillary vessels, supporting a potential benefit in structural remodeling compared with anti-VEGF therapy.

2026-07-01·Ophthalmology and Therapy

Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore

Article

作者: Fukutsu, Kanae ; Cheung, Gemmy C M ; Tan, Gavin S W ; Ong, Charles ; Zheng, Fang ; Tan, Anna C S ; Goh, Rose Ann

INTRODUCTION:

To evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.

METHODS:

This was a retrospective single-center cohort study with chart review. The subjects were patients with DME at the Singapore National Eye Centre who had a suboptimal response to prior therapy and therefore switched to faricimab between 2022 and 2024; all received three or four consecutive intravitreal faricimab injections on the basis of the treating physician's clinical decision. We analyzed changes in best available visual acuity (BAVA; ETDRS letters) and central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to the first follow-up after the loading of faricimab. The initial loading regimen, consisting of three or four consecutive intravitreal faricimab injections, was determined by the treating clinician. We also conducted a subgroup analysis comparing outcomes between the three-injection and four-injection groups.

RESULTS:

A total of 157 eyes from 131 patients were included, comprising 101 eyes in the three-injection group and 56 eyes in the four-injection group. The median duration of prior therapy was 1.8 years (interquartile range [IQR] 3.6). Mean BAVA improved significantly from 57.8 ± 16.5 to 62.4 ± 15.0 ETDRS letters at mean final follow-up of 6.9 weeks (p < 0.001). Mean CST decreased from 431.4 ± 129.4 µm to 334.2 ± 90 µm (p < 0.001). No significant differences in BAVA change (p = 0.39) or CST change (p = 0.58) were observed between the three‑ and four‑injection groups.

CONCLUSION:

Switching to faricimab resulted in significant short-term improvements in both visual acuity and retinal thickness even among patients with chronic DME who were previously receiving long-term treatment.

2026-07-01·Ophthalmology and Therapy

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema

Article

作者: Baldascino, Antonio ; Lupo, Stefano ; Guillot, Antonio ; De Luca, Laura ; Calabro, Mattia ; Meduri, Alessandro ; Vingolo, Enzo Maria ; Menna, Feliciana

INTRODUCTION:

Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints. Microperimetry offers a sensitive and spatially resolved assessment of macular function and may better reflect early neurosensory changes.

METHODS:

This real-world, retrospective comparative cohort study included 60 treatment-naïve eyes of 60 patients with center-involving DME treated at Ospedale Fiorini di Terracina. Thirty eyes received intravitreal aflibercept 8 mg and 30 eyes received intravitreal faricimab 6 mg as three consecutive monthly injections. Outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain optical coherence tomography, and mean retinal sensitivity (RS) assessed using Nidek MP-3 microperimetry. Statistical analyses included paired and unpaired t tests, repeated-measures analysis of variance, odds ratios (OR) for achieving a ≥ 3 dB RS gain, and Pearson correlation analyses.

RESULTS:

Both treatments significantly improved BCVA and CRT after the loading phase, with slightly greater improvements observed in the faricimab group, although not statistically significant. Mean CRT reduction was - 122 ± 47 µm with aflibercept 8 mg and - 138 ± 52 µm with faricimab (p = 0.21). BCVA improved by + 5.8 ± 4.9 and + 7.2 ± 5.4 letters, respectively (p = 0.17). Retinal sensitivity increased in both groups, with a greater gain observed with faricimab (+ 4.8 ± 1.9 dB) compared with aflibercept (+ 2.1 ± 1.6 dB; p < 0.001). Faricimab-treated eyes were more likely to achieve a ≥ 3 dB RS improvement (OR 3.2; 95% CI 1.4-7.6). RS improvement correlated with CRT reduction (r = 0.42) and BCVA gain (r = 0.57).

CONCLUSION:

Despite similar anatomical and visual acuity outcomes, faricimab was associated with greater short-term improvement in retinal sensitivity compared with aflibercept 8 mg during the loading phase. These findings support microperimetry as a sensitive functional endpoint in DME research and selected clinical settings.

1,227

项与法瑞西单抗相关的新闻（医药）

2026-07-23

·氨基观察

首家美国Biotech计划赴港IPO；医保局："十四五"追回医保基金近1182亿元

本期聚焦的医药产业核心事件包括：首家美国Biotech计划赴港IPO、恒瑞法米替尼联合卡瑞利珠单抗获批宫颈癌一线去化疗，海思科思普可泮片获批成全球首个每日一次口服CFB抑制剂，GSK肺癌新药106亿美元收购兑现获FDA批准，Revolution Pan-RAS抑制剂上市申请获得受理，罗氏H1营收384亿美元增长6%，汇宇制药与同源康TY-9591合作纠纷进入诉讼等 ◍市场速递政策 · 产业动态 7/23 国家医保局："十四五"追回医保基金近1182亿元，飞检查处11.6亿元 7月23日，国家医保局发文表示，"十四五"时期全国医保系统共追回医保基金1181.98亿元，协议处理定点医药机构187.96万家。今年1至6月，国家飞检覆盖全国所有省份，检查2926家定点医药机构，查处涉嫌违法违规金额11.6亿元。上半年320种重点监测易倒卖回流药品医保支出同比减少192亿元，下降20%。医保智能监管事前提醒2.49亿人次，事中拒付82.68亿元，全国定点医药机构事前提醒系统接入率达71%。解读：大数据+智能监管织密防线，回流药专项治理成效显著，基金监管从"不敢骗"迈向"不能骗"。 7/23 科伦药业聘任前先声副总裁史瑞文为常务副总经理，分管产业板块 7月22日，科伦药业公告，聘任史瑞文担任公司常务副总经理，分管产业板块。史瑞文博士拥有加拿大美国双国籍，英属哥伦比亚大学药学博士学位，深耕药物研发三十余年，具跨国药企研发管理及本土药企产业化双重经验。曾任职强生附属ALZA、艾尔建等美国知名药企，2017年回国加入先声药业任集团副总裁，主导先诺欣、科赛拉（全球首创化疗前骨髓保护创新药）等多款创新药商业化进程。解读：资深产业化操盘手加盟，科伦加码创新药商业化，从大输液向创新转型再添将才。 7/22 汇宇制药与同源康医药TY-9591合作协议纠纷进入诉讼，双方互提确认之诉 7月22日，汇宇制药发布公告，收到长兴县人民法院传票，浙江同源康医药向法院提起诉讼，请求确认双方《关于TY-9591产品的合作协议》《全国总代理协议》不成立。在此之前，汇宇制药及子公司汇辰昕已就相关合同纠纷向内江市市中区人民法院提起确认之诉，请求确认相关协议合法有效。上述案件均已立案受理，尚未开庭审理。此前同源康已将TY-9591（第三代EGFR-TKI）与齐鲁制药达成超27亿元合作，此次诉讼凸显BD合作中权益界定的重要性。解读：同一管线多方合作引发权益争议，BD合同条款严谨性至关重要，诉讼结果将影响TY-9591商业化格局。 ◍资本信息行情 · 融资 · IPO 7/23 剂泰科技大涨15%领涨AI制药板块 7月23日，剂泰科技-P（07666.HK）高开高走，一度大涨15.18%，领涨AI制药板块。国泰海通证券发研报指，剂泰科技拥有中国首个完成III期临床的AI赋能制剂新药MTS-004，自研全球首个AI纳米递送平台NanoForge，建成全球最大千万级可电离脂质库。公司采用"平台合作+产品合作"双轮驱动模式，全球超30个制药合作伙伴。给予2026年50倍PS，目标价18.71港元，评级"增持"。申万宏源亦首次覆盖给予"买入"。解读：AI制药平台商业模式获验证，首个III期临床产品+双轮驱动，AI制药迎来商业化兑现期。 7/23 首家美国Biotech计划赴港IPO，Axiom Biosciences瞄准2027年香港上市 7月23日，总部位于美国圣地亚哥的临床阶段生物科技公司Axiom Biosciences宣布计划于2027年赴香港联交所IPO，若顺利完成将成为全球首家以香港作为首发上市地的美国生物科技公司。Axiom于2018年成立，业务覆盖细胞治疗、靶向生物制剂、AI辅助药物设计三大赛道。解读：18A制度吸引力外溢，美国Biotech赴港首发或拉开序幕，港股创新药生态持续扩容。 ◍医药动态国内获批 · 临床进展 7/23 恒瑞法米替尼联合卡瑞利珠单抗获批新适应症，宫颈癌一线首个去化疗方案 7月23日，NMPA官网显示，恒瑞医药1类新药法米替尼获批第2项适应症，联合卡瑞利珠单抗用于复发或转移性宫颈癌一线治疗，成为该领域首个去化疗方案。法米替尼为多靶点酪氨酸激酶抑制剂（PDGFR-β、VEGFR、c-Kit）。获批基于III期SHR-1210-III-329研究（443例患者），中位PFS 11.1个月 vs 化疗7.5个月（HR=0.68），中位OS 34.4个月 vs 23.4个月（HR=0.65），数据已在2025年ESMO大会以LBA口头报告发布。解读：宫颈癌一线首个去化疗方案落地，PD-1+抗血管生成组合疗效显著，恒瑞肿瘤管线再下一城。 7/23 海思科思普可泮片获批上市，全球首个每日一次口服补体B因子抑制剂 7月23日，NMPA批准海思科1类创新药琥珀酸思普可泮片（HSK39297）上市，用于既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者。该药为全球首个每日一次口服给药的补体B因子（CFB）抑制剂，此前全球仅有的两款CFB抑制剂（诺华伊普可泮、国产兰诺可泮）均需每日两次。两项III期研究数据入选2026年EHA大会。海思科正拓展狼疮肾炎（II期）、IgA肾病（III期，已纳入突破性治疗）等适应症。6月已将该药海外权益许可给美国Nuvectis Pharma。解读：全球首个日一次口服CFB抑制剂，依从性升维，中国补体药物创新迈入全球第一梯队。 7/23 国药现代达格列净片、阿卡波糖片获药品注册证书，视同通过一致性评价 7月23日，国药现代（600420.SH）公告，收到国家药监局签发的达格列净片及阿卡波糖片《药品注册证书》，均按化学药品4类获批，视同通过一致性评价。达格列净片适用于成人2型糖尿病及HFrEF、CKD、DKD等扩展适应症，阿卡波糖片用于2型糖尿病和糖耐量低减者。两款产品均为糖尿病大品种，本次获批将进一步丰富公司产品结构，提升市场竞争力。解读：糖尿病两大品种获批，SGLT2抑制剂+α-糖苷酶抑制剂组合，国药现代慢病管线持续扩容。 ◍海外药闻 MNC · 获批 7/23 阿斯利康乳腺癌新药Etcamah欧盟获批，唯一一线口服SERD 7月23日，阿斯利康宣布Etcamah（camizestrant）联合CDK4/6抑制剂在欧盟获批，用于ESR1突变的ER阳性、HER2阴性局部晚期或转移性乳腺癌一线治疗。Etcamah是目前唯一获批用于乳腺癌一线治疗的新一代口服SERD，此前已在日本、阿联酋、沙特获批。获批基于III期SERENA-6研究（315例），ctDNA检测ESR1突变后提前换药，疾病进展或死亡风险降低56%（HR=0.44），中位PFS 16个月 vs 9.2个月。值得注意的是，美国FDA ODAC曾以3:6投票不支持该药上市，PDUFA日期已延长审查补充数据。解读：ctDNA提前换药策略欧盟获批，口服SERD一线突围 7/22 GSK肺癌新药Jideytro获FDA批准，106亿美元收购Nuvalent加速兑现 7月22日，美国FDA批准GSK的ROS1选择性抑制剂Jideytro（zidesamtinib）上市，用于既往接受过ROS1激酶抑制剂治疗的局部晚期或转移性ROS1阳性NSCLC成人患者，比原定PDUFA日期提前近两个月。该药为GSK今年6月以106亿美元收购Nuvalent所得。获批基于ARROS-1 I/II期研究（117例经治患者），ORR达44%，6个月和12个月DOR率分别为82%和69%。zidesamtinib具备强血脑屏障穿透能力且克服G2032R耐药突变，高选择性设计降低CNS毒性。收购另一核心资产第四代ALK抑制剂Neladalkib正处FDA审评中，预计2026年11月获批，两款药物峰值销售合计37亿至54亿美元。解读：106亿美元收购快速兑现，ROS1+ALK双管线布局肺癌全病程，GSK肿瘤版图加速扩张。 7/23 诺和诺德口服GLP-1R/AMYR双激动剂启动首个减重III期临床，全球最快 7月23日，美国临床试验收录网站显示，诺和诺德启动Zenagamtide（Amycretin）口服片剂首个III期临床AMAZE 9。该药为单分子GLP-1R/胰淀素受体（AMYR）双激动剂，支持每日1次口服给药。AMAZE 9为多中心研究（n=950），评估口服Zenagamtide对比安慰剂辅助低热量饮食在成人肥胖中的减重效果和安全性，主要终点为第76周体重较基线百分比变化。I/II期研究显示，每周1次注射给药36周后体重降低24.3%（安慰剂组1.1%）。目前全球5款靶向Amylin/AMYR的候选药物中，除Zenagamtide外其余4款仅开发注射剂型，口服剂型为全球最快。解读：口服GLP-1R/AMYR双靶减重III期启动，全球最快口服剂型，诺和诺德加码口服减重赛道。 7/22 Revolution Pan-RAS抑制剂Daraxonrasib上市申请获FDA受理 7月22日，Revolution Medicines宣布pan-RAS抑制剂Daraxonrasib上市申请获FDA受理，用于经治转移性胰腺癌（PDAC），已获突破性疗法认证、孤儿药资格及优先审评券。获批基于III期RASolute302研究：Daraxonrasib对比化疗，全人群中位OS 13.2个月 vs 6.7个月（HR=0.40，死亡风险降低60%），中位PFS 7.2个月 vs 3.8个月（HR=0.49），ORR 31.6% vs 11.2%。该药为RAS(ON)抑制剂，对G12、G13、Q61及野生型RAS均有活性，超90%胰腺癌患者携带RAS突变。因药物相关副作用停药率仅1.2%。公司已启动胰腺癌一线、二线、辅助治疗三项III期临床。解读：Pan-RAS抑制剂填补靶向治疗空白，有望重塑胰腺癌治疗格局。 7/23 罗氏2026H1营收384亿美元增长6%，减肥管线全面提速 7月23日，罗氏公布2026年上半年业绩，总营收303.64亿瑞士法郎（约384.35亿美元），同比增长6%（CER）。其中制药业务299.10亿美元（+6%），诊断业务85.35亿美元（+3%）。中国区制药收入同比下降9%至18.86亿美元，诊断收入同比下降15%。肿瘤、血液、神经、免疫、眼科五大领域分别收入93.43亿（+1%）、58.01亿（+14%）、62.91亿（+9%）、41.65亿（+8%）、26.67亿美元（+6%）。5款创新药销售额超20亿美元（Ocrevus、Hemlibra、Vabysmo、Tecentriq、Xolair）。代谢管线GLP-1R/GIPR激动剂CT-388和Amylin类似物Petrelintide稳步推进。公司维持全年中个位数增长指引。解读：神经+血液领域领涨对冲肿瘤增速放缓，减肥管线加码追赶 7/22 Summit更新HARMONi研究OS数据，依沃西单抗全人群OS HR=0.76 7月22日，Summit Therapeutics更新III期HARMONi研究总生存期（OS）数据。截至2026年6月，西方人群随访时间延长至23.2个月，亚洲人群随访32.7个月。结果显示，依沃西单抗联合化疗组对比安慰剂联合化疗组，西方人群OS HR=0.76，全人群OS HR同样为0.76。该数据已提交FDA作为依沃西单抗上市申请材料的一部分。依沃西单抗为康方生物自主研发的PD-1/VEGF双抗，由Summit获得海外权益，此前已在中国获批上市。解读：OS数据持续获益验证疗效一致性，国产双抗出海能否再进一步有望揭晓

2026-07-23

·FierceBiotech

Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies

Roche may have scrapped work on a T-cell engager (TCE) for lupus, but the company’s head of pharma told Fierce that the drugmaker still has a strategy for developing cell therapies for autoimmune diseases. As part of a wider pipeline clearout disclosed during Roche’s second-quarter earnings results released July 23, the Swiss pharma revealed that it had stopped work on RG6382, a T-cell-engaging bispecific antibody targeting CD19 and CD3. The company had been evaluating the therapy in an ongoing phase 1 open-label study of patients with systemic lupus erythematosus (SLE). But a Roche spokesperson explained to Fierce this morning that after reviewing the data to date, “it has become clear that this molecule does not have the requisite characteristics to move forward in this indication.” “Since SLE was the lead indication for this asset, this discontinuation marks the termination of its development,” the spokesperson added. Autoimmune diseases have become a popular target for cell therapies in recent years —most notably CAR-T therapies, where Kyverna Therapeutics may potentially be first to market with mivocabtagene autoleucel for stiff person syndrome. When Roche struck a $1.5 billion deal to buy Poseida Therapeutics in 2024, the pharma referenced the potential of using the biotech’s cell therapy pipeline, including a BCMAxCD19 CAR-T, to treat autoimmune disease. On a call with journalists this morning, Roche Pharmaceuticals CEO Teresa Graham acknowledged to Fierce that autoimmune disease “was indeed one of the aspects of the Poseida deal.” When asked by Fierce whether Roche is still exploring the potential of cell therapies to treat these diseases, Graham said: “Yes, we do intend to continue development, and we hope to be able to provide some more updates soon.” Today’s pipeline clearout included two drugs in phase 2 development. One of these was CT-868, a once-daily, dual GLP-1/GIP receptor agonist for Type 1 diabetes that Roche had acquired as part of its buyout of Carmot Therapeutics. Despite seeing positive phase 2 data for CT-868, Roche has decided to prioritize another Carmot asset—a once-weekly GLP-1/GIP agonist called enicepatide—for T1D instead. As enicepatide is also being evaluated for obesity, it “makes more sense” for Roche to focus on this program, executives explained on the earnings call. “We believe enicepatide has best-in-disease potential for glycemic control and can deliver maximum therapeutic differentiation for patients living with diabetes,” a spokesperson told Fierce. “Further details regarding our plans for enicepatide in T1D will be shared at a later stage.” The other mid-stage asset thrown on the scrap heap was an anti-Tie2 agonist dubbed RG6351. Roche had been assessing the therapy in the eye disease diabetic macular edema (DME) as both a monotherapy and in combination with Eylea or Vabysmo. However, a look at the data showed a “low probability” of beating Vabysmo, a spokesperson told Fierce. The study “reinforce[d] that dual inhibition of VEGF/Ang-2 with [Vabysmo] is thought to provide robust activation of the Tie2 pathway for patients with DME,” they added. Further back in Roche’s pipeline, the company discontinued a clutch of phase 1-stage drugs. Aside from the TCE, these included mosperafenib, a BRAF inhibitor that was being evaluated for solid tumors. That trial closed in April, a spokesperson told Fierce. “While data from the phase 1a/b trial has shown to be positive, we believe that licensing out this asset to a suitable partner would be the best path forward for this asset and for the wider community,” they added. Mosperafenib was joined on the discard pile by another solid tumor candidate in the form of RG6468, which was being assessed in combination with Tecentriq. Roche didn’t confirm RG6468’s mode of action, but did tell Fierce that the company had decided to halt the program after reviewing the phase 1 data. The company’s second-quarter earnings also reaffirmed Roche’s decision earlier this month to scrap two of its Huntington’s disease prospects , including the phase 2-stage tominersen, which was partnered with Ionis Pharmaceuticals.

临床1期细胞疗法临床2期财报

2026-07-23

·药研网

2026 H1| 罗氏营收增长6%，中国区承压，7款新药迎管线调整

刚刚，罗氏公布了2026H1业绩：截至2024年9月30日, 罗氏 H1 总收入达到304亿瑞士法郎（按平均汇率计算：1 瑞士法郎=1.2736 美元，约387美元）。按固定汇率（CER）计算, 同比增长6%。制药业务：上半年营收为237亿瑞士法郎，+6%（按CER计算，下同），这得益于各治疗领域药品销售额的持续强劲增长：Xolair（过敏性哮喘、慢性荨麻疹、食物过敏）、Hemlibra（A型血友病）、Ocrevus（多发性硬化症）、Phesgo（乳腺癌）和Vabysmo（严重眼部疾病）是主要的增长驱动力。其中，Ocrevus（奥瑞利珠单抗）依旧是最畅销产品，全球销售额为 34.7 亿瑞士法郎，同比增长 7%。诊断事业部：销售额增长3%，这主要得益于免疫诊断和临床化学产品以及病理和分子解决方案的需求增长。 Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2026 vs. YTD June 2025 制药业务从区域来看，美国仍是罗氏制药业务最大贡献市场，上半年收入达122.29亿瑞士法郎，增长 6%。中国区上半年下降了9%，主要受 2025 上半年流感药Xofluza（速福达，玛巴洛沙韦）高基数影响，2026年同期流感相关需求回落。从最新pipeline变动来看，罗氏更新后，共有七款新药被移除，涉及肿瘤、自免、神经退行性疾病及代谢疾病等多个领域：肿瘤管线：BRAF抑制剂mosperafenib退出I期临床； RG6382（CD19/CD3双抗）：此前布局SLE，如今消失； RG6496（HTT SNP ASO）和tominersen：亨廷顿病项目此前属于神经管线，如今已退出；实体瘤候选药物RG6468退出I期临床； Tie2激动抗体G6351退出糖尿病性黄斑水肿（DME）II期临床； 1型糖尿病双靶点激动剂Acmopatide退出II期临床（该项目此前刚在2026年ADA年会上公布II期数据）；此外，ASO药物tominersen也退出亨廷顿病II期临床开发。总之，罗氏上半年业绩强劲，预计2026年集团销售额将进入中个位数区间（CER）。 End 声明：本公众号所发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者，欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。往期回顾 1. ASCO 2026| 中国创新药迎来“高光时刻” 2. 创始人再度减持1.21亿！信达生物为何大跌？ 3. 恒瑞，翻开“新篇章”！

100 项与法瑞西单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11516	法瑞西单抗	-	DB15303

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血管样条纹	日本	Chugai Pharmaceutical Co., Ltd.	2025-05-19
视网膜静脉阻塞相关黄斑水肿	澳大利亚	Roche Products Pty Ltd.	2022-08-08
年龄相关性黄斑变性	日本	Chugai Pharmaceutical Co., Ltd.	2022-03-28
脉络膜新生血管	日本	Chugai Pharmaceutical Co., Ltd.	2022-03-28
黄斑变性	日本	Chugai Pharmaceutical Co., Ltd.	2022-03-28
糖尿病性黄斑水肿	美国	Genentech, Inc.	2022-01-28
湿性年龄相关性黄斑变性	美国	Genentech, Inc.	2022-01-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
视网膜静脉阻塞	申请上市	美国	Roche Holding AG	2023-05-09
伴有糖尿病的增殖性视网膜病变	临床3期	美国	Genentech, Inc.	2025-08-04
近视脉络膜新生血管	临床3期	中国	F. Hoffmann-La Roche Ltd.	2024-02-28
近视脉络膜新生血管	临床3期	中国	罗氏（中国）投资有限公司	2024-02-28
近视脉络膜新生血管	临床3期	澳大利亚	罗氏（中国）投资有限公司	2024-02-28
近视脉络膜新生血管	临床3期	澳大利亚	F. Hoffmann-La Roche Ltd.	2024-02-28
近视脉络膜新生血管	临床3期	法国	罗氏（中国）投资有限公司	2024-02-28
近视脉络膜新生血管	临床3期	法国	F. Hoffmann-La Roche Ltd.	2024-02-28
近视脉络膜新生血管	临床3期	德国	F. Hoffmann-La Roche Ltd.	2024-02-28
近视脉络膜新生血管	临床3期	德国	罗氏（中国）投资有限公司	2024-02-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ALTIMETER (Pubmed \| Ophthalmol Sci)	临床2期	糖尿病性黄斑水肿	99	Faricimab 6.0 mg	製鹹顧壓網廠觸夢繭艱(廠鹹齋鬱壓顧鬱顧繭鏇) = 夢齋廠夢廠製壓蓋壓窪夢蓋憲選鹹蓋構鬱淵範 (簾選構夢憲選蓋繭淵膚, 7.5 ~ 10.9) 更多	积极	2026-05-01
NCT03823287 \| NCT03823300 (TENAYA, Pubmed \| Ophthalmol Sci)	临床3期	湿性年龄相关性黄斑变性	1,329	Faricimab 6 mg	壓鹹觸壓築糧襯顧簾構(鹽繭繭獵蓋構襯積鬱蓋) = 憲獵衊觸鬱選糧構鹽積淵淵糧鏇糧鹹製繭鑰網 (鬱鑰遞遞糧艱襯膚鬱築 ) 更多	积极	2026-05-01
				Aflibercept 2 mg	壓鹹觸壓築糧襯顧簾構(鹽繭繭獵蓋構襯積鬱蓋) = 積鏇繭積顧憲選願艱窪淵淵糧鏇糧鹹製繭鑰網 (鬱鑰遞遞糧艱襯膚鬱築 ) 更多
NCT03622593 (RHINE, Pubmed \| Ophthalmol Ther)	临床3期	糖尿病性黄斑水肿	152	Faricimab 6.0 mg every 8 weeks (Q8W)	鑰選餘簾獵壓鹽顧淵夢(夢膚壓廠壓網簾醖糧廠) = 夢齋膚構憲願顧齋廠齋構選繭願齋膚壓壓鬱窪 (夢憲積餘遞憲艱繭選窪 )	积极	2026-04-10
				Faricimab 6.0 mg treat-and-extend (T&E)	鑰選餘簾獵壓鹽顧淵夢(夢膚壓廠壓網簾醖糧廠) = 淵膚膚鑰膚願簾醖繭齋構選繭願齋膚壓壓鬱窪 (夢憲積餘遞憲艱繭選窪 )
NCT03622593 \| NCT03622580 (YOSEMITE, Pubmed \| Retina)	临床3期	糖尿病性黄斑水肿	1,700	Faricimab Q8W	網積衊獵觸簾糧顧糧遞(齋積壓糧遞壓糧憲鹽醖) = 蓋網網構顧憲範鑰襯鏇顧艱餘窪願鏇鹹構顧積 (遞範衊廠簾願襯網鹹願 ) 更多	积极	2025-11-01
				Faricimab T&E	簾網鹽選糧窪願憲觸鑰(艱獵襯願鬱觸網簾廠壓) = 廠糧獵遞網壓夢願餘鹽獵獵糧築襯積願醖壓壓 (範積願廠遞遞簾醖簾製 )
NCT04777201 (AVONELLE-X, CTgov)	临床3期	湿性年龄相关性黄斑变性	1,036	Anti-VEGF Therapy+Faricimab	遞糧鹹壓構壓壓膚獵鹹 = 窪憲築顧積衊蓋鹹築鹹壓餘網淵網獵鹹餘憲齋 (積壓衊鏇糧鹽構壓淵獵, 醖鏇艱蓋夢鹽鏇構艱艱 ~ 蓋製鹹繭襯構窪鏇壓艱) 更多	-	2025-10-24
NCT04777201 (AVONELLE-X, NEWS \| GlobeNewswire) 人工标引	临床3期	年龄相关性黄斑变性	1,029	Faricimab	簾艱鏇遞壓網構顧鏇鬱(製範願廠製積遞顧築觸) = 醖鏇構衊網獵簾膚鑰繭積艱憲餘艱壓鹽鹽鹽鑰 (憲簾觸餘鹽窪選網蓋築 ) 更多	积极	2025-09-04
				Faricimab (prior aflibercept 2 mg)	簾艱鏇遞壓網構顧鏇鬱(製範願廠製積遞顧築觸) = 鑰製製廠鬱艱觸襯蓋壓積艱憲餘艱壓鹽鹽鹽鑰 (憲簾觸餘鹽窪選網蓋築 ) 更多
CTR20222310 (SALWEEN, NEWS) 人工标引	临床3期	息肉状脉络膜血管病	135	Faricimab	網繭繭壓夢鏇繭網齋鹹(鹽醖膚膚獵鹹齋願壓簾) = 觸選製鹽廠鹹築鏇窪鬱淵憲憲憲繭範膚衊窪獵 (選簾遞鏇膚襯餘艱網醖 ) 更多	积极	2025-09-04
EURETINA2025	N/A	湿性年龄相关性黄斑变性 \| 息肉状脉络膜血管病	76	Faricimab 6.0 mg/0.05 mL	蓋襯夢淵簾積鹹簾鹹製(鹽衊鹽鬱網淵顧顧築淵): P-Value = 0.348 更多	积极	2025-09-04
				Aflibercept 2.0 mg/0.05 mL
NIHONBASHI (EURETINA2025)	临床3期	血管样条纹	24	Faricimab 6.0 mg	鹹範夢選鏇餘壓鹹壓齋(積鑰繭壓顧築醖糧簾觸) = 衊襯憲範簾齋鹽艱願顧艱鑰醖夢積艱顧積壓獵 (夢製齋構壓願鬱廠繭膚, 3.0 ~ 8.5) 更多	积极	2025-09-04
EURETINA2025	N/A	糖尿病性黄斑水肿	3,793	Faricimab	鹽鬱觸顧遞繭築積顧鹹(願壓廠鏇襯獵積鑰廠範): P-Value = 0.17 更多	积极	2025-09-04
				Brolucizumab